On April 14, 2025, Tikvah Management LLC, which owns approximately 1.5% of Quanterix Corp.'s common shares, issued a statement calling on Quanterix to explain its recent purchase agreement for up to $30 million in convertible notes from Akoya Biosciences, Inc.
Tikvah expressed concern over several reasons, including Akoya’s apparent financial distress indicated by its need for bridge financing. The firm also found the commitment of capital before a shareholder vote on the merger to be unusual and coercive.
Furthermore, Tikvah stated that the terms of these convertible notes are significantly off-market and unfair to Quanterix shareholders. Tikvah reiterated its plan to vote AGAINST Quanterix’s proposed merger with Akoya at the upcoming Special Meeting for shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.